Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.58 |
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 7/20 | 0.56 |
| ▸ | RAB9A | P51151 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | CYP1A1 | P04798 | 2/20 | 0.46 |
| ▸ | CYP1B1 | Q16678 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17375252 | 1.00 | MAPT (0.58) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1064135 | 0.79 | CYP1A1 (0.70) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL1064134 | 0.79 | CYP1A1 (0.70) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6093250 | 0.78 | MAPT (0.61) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL6093254 | 0.78 | MAPT (0.61) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL28551727 | 0.78 | NPC1 (0.59) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11980120 | 0.78 | NPC1 (0.59) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22390775 | 0.77 | RAB9A (0.62) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL22390777 | 0.77 | RAB9A (0.62) | MAPTGAANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17375298 | 0.77 | RAB9A (0.62) | MAPTGAANPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221198-B2 | Preparation and medical use of triazenes | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20170158714-A1 | Preparation and Medical Use of Triazenes | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2017-06-08 | — | — | US | disclosed |
| WO-2015197096-A1 | PREPARATION AND MEDICAL USE OF TRIAZENES | ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE (EPFL) (CH) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221198-B2 | Preparation and medical use of triazenes | TBXA2R, XPO5, HIF1AN | MAPT 3299/4885GAA 2091/4885NPC1 1033/4885 |
| US-20170158714-A1 | Preparation and Medical Use of Triazenes | TBXA2R, XPO5, HIF1AN | MAPT 3299/4885GAA 2091/4885NPC1 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.